Antibody response to the COVID-19 ChAdOx1nCov-19 and BNT162b vaccines after temporary suspension of DMARD therapy in immune-mediated inflammatory disease (RESCUE)

OBJECTIVE: To assess the antibody response to disease-modifying antirheumatic drug (DMARD) therapy after the first and second dose of the ChAdOx1nCov-19 (AstraZeneca (AZ)) and BNT162b (Pfizer) vaccines in patients with immune-mediated inflammatory disease (IMID) compared with controls and if withhol...

Descripción completa

Detalles Bibliográficos
Autores principales: Tran, Ai Phuong, Tassone, Daniel, Nossent, Johannes, Ding, Nik Sheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Infections
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9114315/
https://www.ncbi.nlm.nih.gov/pubmed/35577478
http://dx.doi.org/10.1136/rmdopen-2022-002301

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9114315/
https://www.ncbi.nlm.nih.gov/pubmed/35577478
http://dx.doi.org/10.1136/rmdopen-2022-002301

Ejemplares similares